References
Osman S, Danpure HJ. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B 1992;19:183–90.
Pellegrino D, Bonab AA, Dragotakes SC, Pitman JT, Mariani G, Carter EA. Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med 2005;46:1522–30.
Pio BS, Byrne FR, Aranda R, Boulay G, Spicher K, Song MH, et al. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells. Mol Imaging Biol 2003;5:271–7.
Dumarey N, Egrise D, Blocklet D, Stallenberg B, Remmelink M, del Marmol V, et al. Imaging infection with 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med 2006;47:625–32.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yılmaz, S., Ocak, M., Asa, S. et al. The different distribution patterns of FDG and FDG-labelled WBC in inflammatory and infectious lesions. Eur J Nucl Med Mol Imaging 39, 1660–1661 (2012). https://doi.org/10.1007/s00259-012-2170-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-012-2170-4